insights_auto
Outlook: 80.0% bullish·0.0% bearish
Go to analysischevron_right
BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$7.63
arrow_downward
-0.78%(-0.060) 1D
$7.59
arrow_downward
-0.52% (-0.040)todayPre-market
Closed: Nov 9, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$7.76
High
$7.78
Low
$7.54
Mkt. cap
1.96B
Avg. vol.
5.84M
Volume
153.00
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.42
Beta
0.55
Shares outstanding
257.30M
No. of employees
435
Open
$7.76
High
$7.78
Low
$7.54
Mkt. cap
1.96B
Avg. vol.
5.84M
Volume
153.00
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.42
Beta
0.55
Shares outstanding
257.30M
No. of employees
435
News stories
From web sources and news partners
Reuters
·
3 hours ago
S&P 500, Dow futures climb as oil slide lifts sentiment
Yahoo Finance
·
49 minutes ago
Stock market today: Dow, S&P 500, Nasdaq trade mixed ahead of key inflation data
Investor's Business Daily
·
54 minutes ago
Just 3 Of S&P 500's 20 Big Losers Have Recouped Their Nov. 5 Losses
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorHealth Care
IndustryBiotechnology
Websitebiocryst.com